



How OXB Wins: Process development excellence & client-centric delivery

Dr. Nick Clarkson
Head of Process Development

Legal disclaimer

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc (“OXB” or the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and may depend on a number of factors.




Process development is critical to clients' success

Every client's commercial journey starts with process development

100+ PD employees


85+ total client programmes¹

10 process characterisation projects



Leveraging over 30 years of experience to deliver tailored results

Our approach is unique because we ensure maximum yield and quality while offering flexibility



- In-house expertise in virology and molecular biology
- Small scale development for optimisation and application of innovative technologies
- Qualified scale-down models (SDMs) to reduce cost and accelerate timelines
- Platform consistency to leverage past data to the benefit of our clients
- Collaboration is central to how we work. Flexible and tailored approach according to client needs


Different offerings to meet client specific needs

Not one size fits all – each process must respond to specific needs

Fast to GMP

Small scale to Pilot scale in 7 to 9 months


- Lower cost and faster route to GMP and clinic
- Suitable for emerging biotech's and start-ups with timeline constraints
- Particularly suited to wild type AAVs or platform LV offering



Derisking GMP

Small scale to Scale Down Model to Pilot scale to reduce risks


- Derisks the development process by providing additional data
- Changes to process parameters are possible during scale down model (SDM)
- Provides more confidence of expected titre and quality



Full optimisation


Evaluate all parameters for fully optimised results

- Widely chosen by pharma and established biotech's
- Conservative route for clients – data useful in later process characterisation
- Allows full optimisation to maximise titre and quality



Fast to GMP offering

Responding to market demand with a new LV & AAV offering




Proceed directly from scale down model to GMP



Leverage platform data and analytics



Faster and cost-effective offering to get to clinical



Skip engineering run enabled by robust and scalable process



Innovations throughout the USP and DSP process



Accelerated analytical development and qualification

Why is this critical now?

- ✓ Allows OXB to **tailor offerings** more effectively to meet clients' specific needs
- ✓ Strengthens OXB's ability to **remain competitive** in the market
- ✓ Maintains OXB at the forefront of the CGT industry

Clients' target profile



Emerging biotechs & start-ups

Innovation is embedded in process development

Our Innovation and PD teams work hand in hand to deliver next-gen technologies to clients


Process development is central to the scale up and introduction of new technologies into GMP manufacturing



- Translates and scales innovation and technology to at scale manufacturing
- Communicates clients' needs to innovation
- Supports manufacturing and troubleshoots clients' issues

Process development onboards clients and works with them throughout development and commercialisation activities

Introduction of a novel anion exchange process from innovation to GMP in 6 months



- Overall process recovery increased 3-fold
- Improved quality of vector
- Acquisition of key client business and roll out to wider client base

Accelerating process development through innovation

Harnessing the power of DOE and automation to reduce time, cost and complexity

What OXB brings


- Statistical approach to determine how input variables affect outputs
- Automation of Design of Experiments (DoE) and analytics to increase speed
- Multiple factors analysed simultaneously
- Platform data and years of knowledge to interpret results and make quick decisions

What it means for our clients

- Fewer experiments required to achieve the best conditions
- Faster onboarding and progression to Process Characterisation
- Faster to GMP
- Faster batch release
- Robust and automated processes

What it means for OXB


- ✓ Increases ability to service more clients
- ✓ Reinforces market-leading reputation for speed and quality
- ✓ Reduces error rates – right first time



De-risking the path to commercial manufacturing

Our in-depth knowledge supports client success at critical inflection points

What OXB brings



What it means for our clients

- **Faster development timelines** versus traditional process development
- **Lower development cost** through reduced experimental burden
- **Faster progression to key milestones** (PC → PPQ → filing)
- **Reduced risk** through prior knowledge and regulatory alignment
- **Greater confidence in execution** from early development to commercialisation


What it means for OXB

- ✓ More late-stage programmes
- ✓ Go-to CDMO for late-stage programmes

Accelerating development through established platform leverage

Client case study

OXB platform-based approach enabled delivery **6 months earlier**



Challenges

Process Characterisation (PC) requires extensive experimental studies to assess many parameters

- ✓ **Long timelines**
- ✓ **High experimental burden**
- ✓ **Increased development and scale-up costs**



OXB approach

- Leveraged **historical process data**
- Focused on parameters with genuine uncertainty or potential impact
- Excluded well-understood parameters from experimental evaluation



The impacts

- Accelerated **commercialisation timelines**
- **Reduced resource use and development costs**
- More efficient, knowledge-driven PC strategy without compromising process understanding or quality

Continued success is due to our client-centric model

1

Track record

30+ years of experience

2

Unrivalled technical excellence

Deep knowledge of our vector platforms

3

Flexibility to match client needs

Ability to rapidly optimise

4

Acceleration of programmes

Ability to leverage data to deliver results without compromising on quality

5

Extensive commercialisation experience

Significant number of late-stage projects and commercial filings

6

Repeat business

Client satisfaction means we will often have several assets in a portfolio

Let's deliver life-changing therapies together

A global quality and innovation-led
CDMO in cell and gene therapy

[OXB.com](https://www.oxb.com)

